MARKET

TRVI

TRVI

Trevi Therapeutics
NASDAQ
3.400
-0.070
-2.02%
Opening 10:01 03/28 EDT
OPEN
3.470
PREV CLOSE
3.470
HIGH
3.500
LOW
3.390
VOLUME
14.63K
TURNOVER
0
52 WEEK HIGH
4.000
52 WEEK LOW
0.9700
MARKET CAP
234.46M
P/E (TTM)
-11.5843
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at TRVI last week (0318-0322)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Trevi Therapeutics (TRVI), Oculis Holding (OCS) and Quanterix (QTRX)
Trevi Therapeutics, Oculis Holding and Quanterix have 3 analysts with bullish sentiments on the Healthcare sector. Trevi has a Buy rating from Leerink Partners and is expected to make a move soon. The 3 stocks are most likely to make moves following their insider activities.
TipRanks · 3d ago
Buy Rating for Trevi Therapeutics Anchored on Haduvio’s Clinical Promise and Market Potential
TipRanks · 6d ago
Trevi Therapeutics Is Maintained at Outperform by Oppenheimer
Dow Jones · 03/21 13:02
Trevi Therapeutics Price Target Maintained With a $9.00/Share by Oppenheimer
Dow Jones · 03/21 13:02
Oppenheimer Maintains Outperform on Trevi Therapeutics, Maintains $9 Price Target
Benzinga · 03/21 12:56
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vor Biopharma (VOR), Roche Holding AG (OtherRHHVF) and Trevi Therapeutics (TRVI)
TipRanks · 03/21 11:50
Trevi Therapeutics (TRVI) Receives a Buy from Stifel Nicolaus
TipRanks · 03/21 11:27
More
About TRVI
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed k-opioid receptor agonist and mu-opioid receptor antagonist. It is conducting Phase IIb/III clinical trial of Hadguvio in patients with severe pruritus associated with prurigo nodularis. It has also conducted a Phase II clinical trial of Haduvio for chronic cough in patients with IPF, which is referred to as the Phase II CANAL trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.

Webull offers Trevi Therapeutics Inc stock information, including NASDAQ: TRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TRVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TRVI stock methods without spending real money on the virtual paper trading platform.